Lexaria Bioscience Corp. (NASDAQ: LEXX) CEO Chris Bunka noted that Lexaria would continue to see significant milestones in utilizing its patented DehydraTECH drug delivery technology in 2022. “Calendar 2022 will continue to see significant milestones utilizing DehydraTECH-CBD for investigation of heart disease and hypertension; and separately, for oral nicotine delivery as an alternative to smoking… We are delighted to announce that DehydraTECH as an enhanced drug delivery platform will also be evaluated for characteristics and potential treatment options for hormone replacement, dementia, rheumatoid disease and diabetes,” a recent article quotes Bunka as saying. Lexaria received independent review board approval, marking a significant milestone for its 2022 R&D program. “The approval sets the stage for the HYPER-H21-4 study that could define Lexaria’s future. The HOR-A22-1 study, scheduled to start in April 2022, will evaluate DehydraTECH’s ability to enhance the delivery characteristics of estrogen. DEM-A22-1, expected to begin in July 2022, will evaluate DehydraTECH-CBD with or without nicotine for the potential treatment of dementia. Lexaria also plans to execute on the RHEUM-A22-1 and DIAB-A22-1 studies, scheduled for October and November, respectively…”

To view the full article, visit https://cnw.fm/HGULY

About Lexaria Bioscience Corp.

Lexaria’s patented drug delivery technology, DehydraTECH(TM), improves the way active pharmaceutical ingredients (“APIs”) enter the bloodstream by promoting more effective oral delivery. Since 2016, DehydraTECH has repeatedly demonstrated the ability to increase bio-absorption with cannabinoids and nicotine by 5-10x and, in some instances with cannabinoids by as much as 27x compared to standard industry formulations, reduce time of onset from one to two hours to minutes, and mask unwanted tastes. The technology is also being evaluated for orally administered anti-viral drugs, non-steroidal anti-inflammatory drugs (“NSAIDs”), PDE5 inhibitors and more. DehydraTECH has also evidenced an ability to deliver some drugs more effectively across the blood brain barrier. Lexaria operates a licensed in-house research laboratory and holds a robust intellectual property portfolio with 23 patents granted and over 50 patents pending worldwide. For more information, visit the company’s website at www.LexariaBioscience.com.

NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://cnw.fm/LEXX

About CannabisNewsWire

CannabisNewsWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge.

To receive SMS text alerts from CannabisNewsWire, text “CANNABIS” to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW? Ask our Editor

CannabisNewsWire (CNW)
Denver, Colorado
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is part of the InvestorBrandNetwork.

The Brain Tumor Charity recently announced that it had received clearance to conduct a trial to evaluate the effectiveness of a marijuana-based drug in the treatment of recurrent glioblastoma. The general public supported a campaign to raise £400,000 ($532,000) for the charity, which would finance the three-year trial.

The research, which will be led by a University of Leeds expert, will examine whether incorporating the use of an oral spray called Sativex, which contains cannabinoids, in chemotherapy could prolong life for individuals who have been diagnosed with recurrent glioblastoma. This is in addition to evaluating whether the addition of the cannabinoid spray to chemotherapy will improve patient quality of life and/or delay the disease’s progression.

The average rate of survival after diagnosis for this aggressive type of brain cancer, even after patients undergo intensive treatment, is 12 to 18 months. Research has shown that this aggressive form of cancer is common, with figures showing that more than 2,000 individuals are diagnosed with this form of brain cancer annually in England.

The rate of growth of glioblastomas is also high in comparison to other cancers, with researchers finding that for untreated glioblastomas, the rate was 1.4% per day.

The trial plans to recruit 230 patients from 15 hospitals across the United Kingdom early in 2022. University of Leeds Professor Susan Short, who is the principal investigator on the study, stated that the treatment of glioblastomas was challenging. Short, who has majored in neuro-oncology and clinical oncology, explained that even with chemotherapy, radiotherapy and surgery, almost all of these brain tumors regrew in a year, noting that this meant that patients were left with few options.

Short highlighted the growing interest in cannabinoids and their use in various cancers, adding that these compounds had well-described effects in the brain. In addition, Short explained that research had shown that glioblastoma brain tumors had receptors to cannabinoids on their cell surface, citing lab studies which had demonstrated that cannabinoid-based drugs worked well when added to temozolomide chemotherapy and could slow tumor growth. The researchers added that they were excited to add to these previous findings and evaluate whether the drug could extend the lives of glioblastoma patients.

Brain Tumor Charity’s interim chief executive Dr. David Jenkinson asserted that researchers were excited to conduct this world-first trial in the United Kingdom. In addition to having Olympic champion Tom Daley back the trial, Leeds Hospital Charity donated £45,000 ($60,000) to the campaign.

This trial could add further credence to the existence of medicinal cannabis products manufactured by companies such as Simply Sonoma Inc.

NOTE TO INVESTORS: The latest news and updates relating to Simply Sonoma Inc. are available in the company’s newsroom at https://cnw.fm/Sonoma

About CNW420

CNW420 spotlights the latest developments in the rapidly evolving cannabis industry through the release of two informative articles each business day. Our concise, informative content serves as a gateway for investors interested in the legalized cannabis sector and provides updates on how regulatory developments may impact financial markets. Articles are released each business day at 4:20 a.m. and 4:20 p.m. Eastern – our tribute to the time synonymous with cannabis culture. If marijuana and the burgeoning industry surrounding it are on your radar, CNW420 is for you! Check back daily to stay up-to-date on the latest milestones in the fast -changing world of cannabis.

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CNW420.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW420, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW420? Ask our Editor

CannabisNewsWire420
Denver, Colorado
http://www.CNW420.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CNW420 is part of the InvestorBrandNetwork.

In a recent interview, Senate Majority Leader Chuck Schumer revealed that he and his colleagues who are working to advance a bill to legalize cannabis at the federal level have a consensus to not get involved in the marijuana banking legislation until more broad reforms are advanced. Schumer noted that he was open to exploring alternative ways to advance the banking reform if legislators were able to include social equity provisions of legalization, such as expungements for previous marijuana convictions, into the defense policy bill that the chamber will be discussing in the coming weeks.

The interview was conducted on the Psychoactive podcast by Ethan Nadelmann, who is the founder of Drug Policy Alliance.

The majority leader stated that there was an agreement between Sens. Cory Booker and Ron Wyden, who is chairman of the Senate Finance Committee, to block the banking bill, which would offer protection to financial institutions that work with state-legal marijuana businesses. That is, of course, until a legalization bill that was social equity centered was advanced.

The bipartisan bill, dubbed the SAFE Banking Act (Secure and Fair Enforcement), has a strong chance of being approved in Congress, having already been passed by the House of Representatives a few times now. The House is set to pass a separate legalization initiative, sponsored by Chairman Jerrold Nadler, that is similar to the proposal to end federal prohibition on cannabis, which Schumer is sponsoring.

In the interview, Schumer stated that letting the banking legislation be approved would only make it longer and harder to pass comprehensive reform. He explained that the suffering people had to endure wouldn’t be reduced simply because banks could be allowed to fund the growing and processing of marijuana, noting that the quickest way to approve the banking act as well as federally legalize cannabis would be together.

Schumer added that letting the banking legislation be approved would also make it harder to get more conservatives on the federal cannabis legalization bill. However, the majority leader didn’t eliminate the possibility of including some marijuana reform initiatives to the Senate’s version of the National Defense Authorization Act if other provisions focused on justice could be added.

The SAFE Banking Act was attached to this defense legislation, which lacks most of the social equity provisions that activists would like to see. Schumer did recognize that allowing banks to work with cannabis businesses without incurring penalties would allow some disadvantaged communities to obtain access to capital required to take part in the market.

In the long run, all cannabis industry actors, including Hero Technologies Inc. (OTC: HENC), would be better off after comprehensive federal legalization is implemented rather than the piecemeal approach being pushed by some industry advocates.

NOTE TO INVESTORS: The latest news and updates relating to Hero Technologies Inc. (OTC: HENC) are available in the company’s newsroom at https://cnw.fm/HENC

About CNW420

CNW420 spotlights the latest developments in the rapidly evolving cannabis industry through the release of two informative articles each business day. Our concise, informative content serves as a gateway for investors interested in the legalized cannabis sector and provides updates on how regulatory developments may impact financial markets. Articles are released each business day at 4:20 a.m. and 4:20 p.m. Eastern – our tribute to the time synonymous with cannabis culture. If marijuana and the burgeoning industry surrounding it are on your radar, CNW420 is for you! Check back daily to stay up-to-date on the latest milestones in the fast -changing world of cannabis.

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CNW420.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW420, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW420? Ask our Editor

CannabisNewsWire420
Denver, Colorado
http://www.CNW420.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CNW420 is part of the InvestorBrandNetwork.

Hero Technologies (OTC: HENC) and its wholly owned subsidiary Veteran Hemp Company vow to hold themselves and their products to the highest of standards as the cannabis industry grows and an increasing number of companies rush to enter the space. In addition to setting a high bar of distinction in the dynamic marketplace, the subsidiary offers another unique aspect to cannabis company ownership in its founding by veterans. “Initially, this group of entrepreneurial veterans found a nook in the American cannabis industry on the security side of things. They started, grew and then sold several cannabis security companies before deciding that they wanted to focus their talents and hard-earned knowledge of cannabis businesses into a far more product-focused role,” reads a recent article discussing the company’s positioning. “We began offering our sales, marketing and business development consulting to burgeoning cannabis industries to enable our clients to expand their platform and sell more product,” the company’s story states (https://cnw.fm/TkdB4). “Eventually, we decided that our passion for improving the standard and accessibility of cannabis products needed a more direct approach. And, so, we founded Veteran Hemp Company.” To view the full article, visit https://cnw.fm/2UR68 About Hero Technologies Inc. Hero Technologies is a cannabis company working toward a vertically integrated business model. The company owns a majority stake in BlackBox Systems and Technologies LLC, an aeroponic cannabis cultivation system that provides optimal growing conditions to enhance photosynthesis and cultivation of large flowering plants, creating increased harvest efficiencies. Hero Technologies’ strategic business plan includes cannabis genetic engineering, farmland for both medical and recreational cannabis cultivation, production licenses, distribution licenses, consumer packaging, and retail and dispensary operations that make the company a multi-state operator (“MSO”). For more information about the company, visit www.HeroTechnologiesInc.com. NOTE TO INVESTORS: The latest news and updates relating to HENC are available in the company’s newsroom at https://cnw.fm/HENC About CannabisNewsWire CannabisNewsWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge. To receive SMS text alerts from CannabisNewsWire, text “CANNABIS” to 21000 (U.S. Mobile Phones Only) For more information please visit https://www.CannabisNewsWire.com Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer Do you have questions or are you interested in working with CNW? Ask our Editor CannabisNewsWire (CNW) Denver, Colorado www.CannabisNewsWire.com 303.498.7722 Office Editor@CannabisNewsWire.com CannabisNewsWire is part of the InvestorBrandNetwork.

The road to cannabis reform has been long, tedious and fraught with hurdles. After decades of prohibition, anti-marijuana propaganda and harsh policing, reforming cannabis laws and changing the public’s perception towards cannabis was bound to be a challenge.

While reform advocates argued that legalizing cannabis would offer a much-needed reprieve to the minority communities that had suffered the most from the failed war on drugs in addition to creating new jobs and filling state coffers with tax revenue, opponents said that it would inevitably lead to increased drug use, especially among the youth, and promote criminal activity.

However, studies have revealed that there has been minimal or no increase in teen cannabis use in states with legal markets. Furthermore, a top federal officer who previously believed that marijuana use among adolescents would increase after the passage of cannabis legalization bills has conceded that things have played out differently. Speaking at the Psychoactive Podcast hosted by Drug Policy Alliance Founder Ethan Nadelmann, the National Institute on Drug Abuse (“NIDA”) director Nora Volkov discussed a wide variety of drug policy issues. She said that the country’s booming state-legal cannabis industry has not led to a rise in marijuana use among the youth.

Volkov also talked about how the country needs to stop looking at drug abuse and addiction as criminal activity deserving of punitive action and instead approach it as a public health matter, an issue she has covered extensively before. Additionally, she and Nadelmann discussed the medical potential of a variety of psychedelics that federal law has long classified as dangerous.

The effects of cannabis legislation have varied greatly on a state-by-state basis, she says, with some states having better outcomes and others seeing the adverse effects of cannabis use. As such, she noted, it is crucial for federal officials and policymakers to understand which cannabis policies promote the best outcomes while protecting the populace from the negative effects.

Despite more than 30 states passing at least one form of cannabis legislation, federal law, which classifies cannabis as a Schedule 1 controlled substance with no medical application, has held the nascent cannabis sector back. Federal law has created major research barriers, forcing scientists interested in studying cannabis to go through “extremely cumbersome” processes to obtain cannabis, she says. Additionally, scientists are only allowed to use the low-quality cannabis grown at a facility at the University of Mississippi, but Volkov says she has been heartened by moves to increase the number of sanctioned cannabis providers by the Drug Enforcement Administration (“DEA”).

The admission that cannabis legalization doesn’t increase teen marijuana use puts a dent in the collection of misconceptions surrounding marijuana, and as those myths and misconceptions are debunked, cannabis sector players such as American Cannabis Partners could enjoy a more favorable working environment, especially when federal legalization is eventually implemented.

NOTE TO INVESTORS: The latest news and updates relating to American Cannabis Partners are available in the company’s newsroom at https://cnw.fm/ACP

About CNW420

CNW420 spotlights the latest developments in the rapidly evolving cannabis industry through the release of two informative articles each business day. Our concise, informative content serves as a gateway for investors interested in the legalized cannabis sector and provides updates on how regulatory developments may impact financial markets. Articles are released each business day at 4:20 a.m. and 4:20 p.m. Eastern – our tribute to the time synonymous with cannabis culture. If marijuana and the burgeoning industry surrounding it are on your radar, CNW420 is for you! Check back daily to stay up-to-date on the latest milestones in the fast -changing world of cannabis.

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CNW420.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW420, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW420? Ask our Editor

CannabisNewsWire420
Denver, Colorado
http://www.CNW420.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CNW420 is part of the InvestorBrandNetwork.

Last week, the U.S. Senate Appropriations committee voted to approve a bill urging federal authorities to create a regulatory mechanism for cannabidiol products and rethink THC restrictions on hemp. These provisions were among others passed by the Senate committee while working on a bill to fund the U.S. Department of Agriculture as well as other federal departments and agencies for next year’s fiscal year. The bill would also maintain a rider, which protects state-level hemp programs from interference by federal authorities.

Below are some of the marijuana-linked provisions supported by the committee, many of which are akin to the resolutions that were advanced through the House in July.

On the subject of the 0.3% THC limit for hemp products established in 2018, senators directed the U.S. Department of Agriculture to conduct a study on whether there was scientific evidence to support the cap. That study should be done by partnering with federal agencies such as the DEA and the Department of Health and Human Services. In the report, the senators noted that the level of allowable THC content in hemp places a heavy burden on producers of hemp.

The senators added that the FDA should continue to develop regulations that allowed the use of cannabidiol products and also issue a policy guiding the enforcement discretion with regard to these products. In this particular provision, the panel noted that the FDA should continue performing its regulatory responsibilities, which include reviewing product applications, enforcement, inspections and conducting research on cannabis-derived compounds such as CBD.

This was in addition to encouraging the federal agency to consider ongoing and existing medical research associated with cannabidiol as well as partner with academic institutions to expand CBD product sampling studies for products already on the U.S. market.

To ensure that hemp businesses and farmers were eligible to take part in loan and insurance programs that are available to participants in various sectors of the economy, the Senate Appropriations Committee also directed that the Secretary create a dual categorization for industrial hemp as a specialty plant based off of the purpose and manner of cultivating it; that categorization should be created within 90 days of the legislation being enacted.

The draft Senate legislation also has a provision that prevents federally availed money from being used to obstruct state-level hemp programs. This is in addition to extending the terms of a pilot program that has allowed some states in the country to begin growing hemp for CBD and other uses. The 2014 pilot program enabled some states to begin growing hemp before its cultivation was legalized federally by the 2018 Farm Bill.

Increasing the THC limit in the definition of hemp would probably reduce some of the losses that cannabis/hemp growers and processors such as Sonoma Biologics Corp. face due to hemp exceeding the tight THC limits currently in existence.

NOTE TO INVESTORS: The latest news and updates relating to Sonoma Biologics Corp. are available in the company’s newsroom at https://cnw.fm/Sonoma

About CNW420

CNW420 spotlights the latest developments in the rapidly evolving cannabis industry through the release of two informative articles each business day. Our concise, informative content serves as a gateway for investors interested in the legalized cannabis sector and provides updates on how regulatory developments may impact financial markets. Articles are released each business day at 4:20 a.m. and 4:20 p.m. Eastern – our tribute to the time synonymous with cannabis culture. If marijuana and the burgeoning industry surrounding it are on your radar, CNW420 is for you! Check back daily to stay up-to-date on the latest milestones in the fast -changing world of cannabis.

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CNW420.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW420, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW420? Ask our Editor

CannabisNewsWire420
Denver, Colorado
http://www.CNW420.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CNW420 is part of the InvestorBrandNetwork.

Pac Roots (CSE: PACR) (OTCQB: PACRF) (FSE: 4XM), a Canadian company dedicated to producing premium-quality strains and products by leveraging a genetics-focused approach, is committed to quality and excellence, as evidenced by its mantra: quality over quantity. “Pac Roots is focused on elite genetics development and maximizes the quality of its offerings by keeping yields and profit margins high,” reads a recent article. “The company also leverages key partnerships to ensure the superiority of its products. ‘Our mission is to deliver the finest genetics to Canadians,’ the company states. ‘Preserving the excellence of our elite strains while introducing the highest quality of new strains to the public is our passion. Genetic variation and stability are the foundation that drives the decision making for our business.’ Such strong focus and dedication are sure to differentiate Pac Roots Cannabis — even setting it apart from the big-name players in the cannabis space.”

To view the full article, visit https://cnw.fm/i0uJu

About Pac Roots Cannabis Corp.

Pac Roots is the future of genetics. By focusing on elite cannabis genetic development, the company maximizes the quality of its products by keeping yields and profit margins high. Pac Roots subsidizes costs with several strategic partners: Phenome One, one of the largest live genetic libraries in Canada composed of over 350+ live cultivars, as well as its JV partnership with Rock Creek Farms and Speakeasy Cannabis Club, leveraging existing infrastructure, equipment and access to land on a 100-acre hemp project. This combination has the company positioned to be cash-flow positive within their first year of trading. For more information about the company, visit www.PacRoots.ca.

NOTE TO INVESTORS: The latest news and updates relating to PACR are available in the company’s newsroom at http://cnw.fm/PACR

About CannabisNewsWire

CannabisNewsWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge.

To receive SMS text alerts from CannabisNewsWire, text “CANNABIS” to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW? Ask our Editor

CannabisNewsWire (CNW)
Denver, Colorado
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is part of the InvestorBrandNetwork.

Hero Technologies (OTC: HENC), a cannabis company working toward a vertically integrated business model, is paying close attention to Michigan’s medicinal and recreational cannabis sales numbers, which are reaching record highs. This is because its majority-owned subsidiary, BlackBox Systems and Technologies LLC, earlier this year signed a purchase agreement to acquire 120 acres of Michigan farmland for cannabis cultivation. According to HENC CEO Gina Serkasevich, who was quoted in a recent article, the numbers for the company’s cannabis cultivation plan in Michigan, which it anticipates will take anywhere from five to ten years to complete, look exceptionally strong. “We have thoroughly analyzed startup costs, ongoing costs and a wide range of revenue scenarios,” Serkasevich said. “Even our most conservative estimates, using the low-end of the wholesale price range, put us over $1 billion in revenue by the end of our multiphase plan. And the upside potential is much bigger. A higher percentage of retail sales and a higher price per pound could support annual revenue from our Michigan operations in excess of $3 billion.”

To view the full article, visit https://cnw.fm/5JCg6

About Hero Technologies Inc.

Hero Technologies is a cannabis company working toward a vertically integrated business model. The company owns a majority stake in BlackBox Systems and Technologies LLC, an aeroponic cannabis cultivation system that provides optimal growing conditions to enhance photosynthesis and cultivation of large flowering plants, creating increased harvest efficiencies. Hero Technologies’ strategic business plan includes cannabis genetic engineering, farmland for both medical and recreational cannabis cultivation, production licenses, distribution licenses, consumer packaging, and retail and dispensary operations that make the company a multi-state operator (“MSO”). For more information about the company, visit www.HeroTechnologiesinc.com.

NOTE TO INVESTORS: The latest news and updates relating to HENC are available in the company’s newsroom at https://cnw.fm/HENC

About CannabisNewsWire

CannabisNewsWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge.

To receive SMS text alerts from CannabisNewsWire, text “CANNABIS” to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW? Ask our Editor

CannabisNewsWire (CNW)
Denver, Colorado
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is part of the InvestorBrandNetwork.

Gage Growth Corp. (d.b.a. Gage Cannabis) president and director Fabian Monaco recently appeared on Gamechangers LIVE, a podcast series that features individuals who are gamechangers in their fields. During the podcast, which is hosted by Sergio Tigera, guests talk about their journeys and share their mindsets, struggles and successes in an effort to both inspire and inform listeners. During the interview, Monaco discussed Gage’s recent closing of its oversubscribed Regulation A+, Tier 2, equity financing that totaled $50 million, the maximum amount allowed under the company’s offering. Monaco talked about the financing, referencing his extensive background in investment banking and capital markets; he also noted that Gage plans an upcoming initial public offering. Monaco also provided additional insights about the future of the cannabis industry, including the challenges cannabis companies regarding U.S. banking regulations. He also outlined why now is the ideal time for anyone — investors as well as anyone looking for a career in a sector with promising growth — to get into the industry. “The industry continues to move in a positive direction,” said Gage Cannabis president and director Fabian Monaco in the press release. “Right now, it’s probably the most positive it has ever been. I think we’re going to see explosive growth. If you look at the U.S., I think it’s going to be crazy in terms of the growth this year. You’re frequently thrown a curveball in this industry. Things you think will happen fast end up being slow. Things you think are going to be slow end up happening fast. It’s like constantly being on the treadmill at super high speed, just trying to make sure you don’t fall off.”

To view the full interview, visit https://cnw.fm/atdVM

To view the full press release, visit https://cnw.fm/QEMBN

About Gage Cannabis Co.

Gage Cannabis is innovating and curating the highest-quality cannabis experiences possible for cannabis consumers in the state of Michigan and bringing internationally renowned brands to market. Through years of progressive industry experience, the firm’s founding partners have successfully built and grown operations with federal and state licenses, including cultivation, processing and retail locations. Gage’s portfolio includes city and state approvals for 19 Class C cultivation licenses, three processing licenses and 12 provisioning centers (dispensaries). For more information, visit the company website at www.GageUSA.com.   

NOTE TO INVESTORS: The latest news and updates relating to GAGE are available in the company’s newsroom at https://cnw.fm/GAGE

About CannabisNewsWire

CannabisNewsWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge.

To receive SMS text alerts from CannabisNewsWire, text “CANNABIS” to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW? Ask our Editor

CannabisNewsWire (CNW)
Denver, Colorado
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is part of the InvestorBrandNetwork.